About Us
MindRank is an AI-powered drug discovery company.
Our Mission
To transform drug discovery and development by continuously inventing and integrating innovations across machine learning, biology and chemistry. Our ultimate goal is to find better drugs, treat more diseases, and help more patients.
Focusing on Hard-to-Drug Molecular Targets
In addition to speeding up and reducing costs of drug discovery, we aim to discover innovative therapies and increase the overall drug R&D successful rate.
Our Journey
2021
Our former AI solution was selected for funding (multi-million EURO) by the 2020 “Europe Innovative Medicines Initiative” to combat coronavirusMar
Our proprietary AI solution was nominated by Deep Pharma Intelligence as one of the 11 "Top AI Breakthroughs in Biopharma from 2018 to 2020"May
Raised $7M Seed Funding from Sherpa Healthcare PartnersJun
The AI team won 1st place in the "Global Artificial Intelligence Technology Innovation Contest" hosted in Hangzhou, ChinaJul
Delivered an allosteric inhibitor PCC with Best-in-Class potential to a public traded biotech companyAug
Partnership with Antengene (HK:6996) on AI-enabled Drug DiscoveryOct
Partnership with Medicilon (SHA:688202) on AI-enabled Drug DiscoveryDec
Tens of millions US dollar Series A Funding2022
Jan
- AI drug discovery paper published in Nature Biomedical Engineering
- Partnership with Chemexpress (SHA:688131) strengthened in AI-enabled Synthetic Accessibility
- Mindrank's AI-designed proprietary small molecule drug began IND-enabling studies, eight months after program initiation
Jul
Successfully delivered 4 drug discovery projectsDec
Won the 4th China Health Innovation Platform AwardDec
US IND Approval for Mindrank's AI-designed proprietary small molecule GLP-1 RA MDR-0012023
Apr
China CDE Approval for Mindrank's AI-designed proprietary small molecule GLP-1 RA MDR-001Jun
Completed the first healthy volunteer dosed in the Phase 1 study of MDR-001Jul
Secured over $20M in Series A+ FundingSep
Completed the dosing of first cohort in Phase 2a study of MDR-001
Selected Partners
SHA:688202
HK:6996
SHA:688131
Investors
